Myasthenia Gravis Treatment Market

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $4,850	147 Pages	Fortune Business Insights Pvt. Ltd.	October, 2024	FOB19224224

Best Price Guarantee
Price	from $4,850
Length	147 Pages
Publisher	Fortune Business Insights Pvt. Ltd.
Published Date	October, 2024
SKU	FOB19224224

Myasthenia Gravis Treatment Market

Growth Factors of Myasthenia Gravis Treatment Market

The myasthenia gravis treatment market size was valued at USD 1.40 billion in 2023, and the market is now projected to grow from USD 1.51 billion in 2024 to USD 2.75 billion by 2032, exhibiting a CAGR of 7.8% during the forecast period of 2024-2032.

The COVID-19 effect posed as a disruptor on the myasthenia gravis treatment market growth because this posed a high level of risk to immune-compromised patients who received fewer admissions in the year 2020. However, relaxation on lockdowns and high vaccination rates in 2021 and 2022 remained the turning point for patient visits and thus marked a recovery in this market.

Increasing awareness of the treatment, rising diagnosis ratio and the geriatric population boost the myasthenia gravis treatment market share. The good reimbursement policies with new treatment requirements have shifted the pressure towards the key market participants to develop new drugs. Development in medical technology and research and better diagnosis with early treatment contribute to growth in the global market.

Furthermore, key players are working on new therapies for myasthenia gravis due to the side effects of traditional approaches and growing patient expectations. An increase in the diagnosis rates and patients wanting a cure, urge for new research and development of drugs. So the key players focus on subcutaneous Ig (SCIg) therapy, a new trend for the home healthcare requirements for patients with primary immune deficiency. The collaborations of companies and research institutions for the treatment are expanding the market.

Comprehensive Analysis of Myasthenia Gravis Treatment Market

This market expansion of the myasthenia gravis treatment and healthcare industry is useful for performing a detailed regional outlook based on the factors influencing pharmacy products' supply and demand. These segmentations are carefully segmented according to the drug class and distribution channel. The drug class includes, Cholinesterase Inhibitors, Corticosteroids, Immunosuppressants, IVIg and Monoclonal Antibodies. The distribution channel includes, Hospital Pharmacies, Retail Pharmacies and Online Pharmacies.

North America is estimated to grow up to USD 0.69 billion in 2023 owing to the growing cases of myasthenia gravis and the population ageing. Advanced healthcare infrastructure and policies regarding reimbursement are enhancing diagnostic and therapeutic ratios. These factors are considered driving forces that sustain the market growth within the forecast period.

The leading market players have a significant presence in the healthcare industry ensuring industrial prospectus growth and the market trends. These players include, AstraZeneca (Cambridge, U.K.), Astellas Pharma Inc. (Tokyo, Japan), F. Hoffmann-La Roche Ltd. (Basel, Switzerland), Novartis AG (Basel, Switzerland), Veloxis Pharmaceuticals, Inc. (Horsholm, Denmark) and Bausch Health Companies Inc. (Laval, Canada). These market players provide a level-playing competitive landscape.

In October 2023, UCB S.A., a worldwide biopharmaceutical organization, declared that the ZILBRYSQ (zilucoplan) is approved in the USA for GMG and is among all adults, affecting those with anti-acetylcholine receptor (AChR) antibodies.

Segmentation Table

Global Myasthenia Gravis Treatment Market Scope

Study Period 2019-2032

Base Year 2023

Forecast Period 2024-2032

Growth Rate CAGR of 7.8% from 2024 to 2032

Historical Period 2019-2022

Unit Value (USD Billion)

Segmentation By Drug Class, Distribution Channel, and Region

By Drug Class

Cholinesterase Inhibitors

Corticosteroids
Immunosuppressants
IVIg
Monoclonal Antibodies

By Distribution Channel

Hospital Pharmacies

Retail Pharmacies
Online Pharmacies

By Region

North America (By Drug Class, By Distribution Channel, and By Country)

U.S. (By Drug Class)
Canada (By Drug Class)
Europe (By Drug Class, By Distribution Channel, and By Country/Sub-region)
U.K. (By Drug Class)
Germany (By Drug Class)
France (By Drug Class)
Italy (By Drug Class)
Spain (By Drug Class)
Scandinavia (By Drug Class)
Rest of Europe (By Drug Class)
Asia Pacific (By Drug Class, By Distribution Channel, and By Country/Sub-region)
Japan (By Drug Class)
India (By Drug Class)
China (By Drug Class)
Australia (By Drug Class)
Rest of Asia Pacific (By Drug Class)
Rest of the World (By Drug Class, By Distribution Channel)

Please Note: It will take 5-6 business days to complete the report upon order confirmation.

1. Introduction: 1.1. Research Scope; 1.2. Market Segmentation; 1.3. Research Methodology; 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics: 3.1. Market Drivers; 3.2. Market Restraints; 3.3. Market Opportunities
4. Key Insights: 4.1. Key Industry Developments (Mergers, Acquisitions, and Partnership); 4.2. New Product Launches, by Key Players; 4.3. Impact of COVID-19 on the Market
5. Global Myasthenia Gravis Treatment Market Analysis, Insights and Forecast, 2019-2032: 5.1. Market Analysis, Insights and Forecast – By Drug Class; 5.1.1. Cholinesterase Inhibitors; 5.1.2. Corticosteroids; 5.1.3. Immunosuppressants; 5.1.4. IVIg; 5.1.5. Monoclonal Antibodies; 5.2. Market Analysis, Insights and Forecast – By Distribution Channel; 5.2.1. Hospital Pharmacies; 5.2.2. Online Pharmacies; 5.2.3. Retail Pharmacies; 5.3. Market Analysis, Insights and Forecast – By Geography; 5.3.1. North America; 5.3.2. Europe; 5.3.3. Asia Pacific; 5.3.4. Rest of World
6. North America Myasthenia Gravis Treatment Market Analysis, Insights and Forecast, 2019-2032: 6.1. Market Analysis, Insights and Forecast – By Drug Class; 6.1.1. Cholinesterase Inhibitors; 6.1.2. Corticosteroids; 6.1.3. Immunosuppressants; 6.1.4. IVIg; 6.1.5. Monoclonal Antibodies; 6.2. Market Analysis, Insights and Forecast – By Distribution Channel; 6.2.1. Hospital Pharmacies; 6.2.2. Online Pharmacies; 6.2.3. Retail Pharmacies; 6.3. Market Analysis, Insights and Forecast – By Country; 6.3.1. U.S.; 6.3.1.1. By Drug Class; 6.3.2. Canada; 6.3.2.1. By Drug Class
7. Europe Myasthenia Gravis Treatment Market Analysis, Insights and Forecast, 2019-2032: 7.1. Market Analysis, Insights and Forecast – By Drug Class; 7.1.1. Cholinesterase Inhibitors; 7.1.2. Corticosteroids; 7.1.3. Immunosuppressants; 7.1.4. IVIg; 7.1.5. Monoclonal Antibodies; 7.2. Market Analysis, Insights and Forecast – By Distribution Channel; 7.2.1. Hospital Pharmacies; 7.2.2. Online Pharmacies; 7.2.3. Retail Pharmacies; 7.3. Market Analysis, Insights and Forecast – By Country/ Sub-region; 7.3.1. U.K.; 7.3.1.1. By Drug Class; 7.3.2. Germany; 7.3.2.1. By Drug Class; 7.3.3. France; 7.3.3.1. By Drug Class; 7.3.4. Spain; 7.3.4.1. By Drug Class; 7.3.5. Italy; 7.3.5.1. By Drug Class; 7.3.6. Scandinavia; 7.3.6.1. By Drug Class; 7.3.7. Rest of Europe; 7.3.7.1. By Drug Class
8. Asia Pacific Myasthenia Gravis Treatment Market Analysis, Insights and Forecast, 2019-2032: 8.1. Market Analysis, Insights and Forecast – By Drug Class; 8.1.1. Cholinesterase Inhibitors; 8.1.2. Corticosteroids; 8.1.3. Immunosuppressants; 8.1.4. IVIg; 8.1.5. Monoclonal Antibodies; 8.2. Market Analysis, Insights and Forecast – By Distribution Channel; 8.2.1. Hospital Pharmacies; 8.2.2. Online Pharmacies; 8.2.3. Retail Pharmacies; 8.3. Market Analysis, Insights and Forecast – By Country/ Sub-region; 8.3.1. Japan; 8.3.1.1. By Drug Class; 8.3.2. China; 8.3.2.1. By Drug Class; 8.3.3. India; 8.3.3.1. By Drug Class; 8.3.4. Australia; 8.3.4.1. By Drug Class; 8.3.5. Rest of Asia Pacific; 8.3.5.1. By Drug Class
9. Rest of World Myasthenia Gravis Treatment Market Analysis, Insights and Forecast, 2019-2032: 9.1. Market Analysis, Insights and Forecast – By Drug Class; 9.1.1. Cholinesterase Inhibitors; 9.1.2. Corticosteroids; 9.1.3. Immunosuppressants; 9.1.4. IVIg; 9.1.5. Monoclonal Antibodies; 9.2. Market Analysis, Insights and Forecast – By Distribution Channel; 9.2.1. Hospital Pharmacies; 9.2.2. Online Pharmacies; 9.2.3. Retail Pharmacies
10. Competitive Analysis: 10.1. Global Market Share Analysis (2023); 10.2. Company Profiles; 10.2.1. AstraZeneca; 10.2.1.1. Overview; 10.2.1.2. Products & Services; 10.2.1.3. SWOT Analysis; 10.2.1.4. Recent Developments; 10.2.1.5. Strategies; 10.2.1.6. Financials (Based on Availability); 10.2.2. Astellas Pharma Inc.; 10.2.2.1. Overview; 10.2.2.2. Products & Services; 10.2.2.3. SWOT Analysis; 10.2.2.4. Recent Developments; 10.2.2.5. Strategies; 10.2.2.6. Financials (Based on Availability); 10.2.3. F. Hoffmann-La Roche Ltd.; 10.2.3.1. Overview; 10.2.3.2. Products & Services; 10.2.3.3. SWOT Analysis; 10.2.3.4. Recent Developments; 10.2.3.5. Strategies; 10.2.3.6. Financials (Based on Availability); 10.2.4. Novartis AG; 10.2.4.1. Overview; 10.2.4.2. Products & Services; 10.2.4.3. SWOT Analysis; 10.2.4.4. Recent Developments; 10.2.4.5. Strategies; 10.2.4.6. Financials (Based on Availability); 10.2.5. Veloxis Pharmaceuticals, Inc.; 10.2.5.1. Overview; 10.2.5.2. Products & Services; 10.2.5.3. SWOT Analysis; 10.2.5.4. Recent Developments; 10.2.5.5. Strategies; 10.2.5.6. Financials (Based on Availability); 10.2.6. Bausch Health Companies Inc.; 10.2.6.1. Overview; 10.2.6.2. Products & Services; 10.2.6.3. SWOT Analysis; 10.2.6.4. Recent Developments; 10.2.6.5. Strategies; 10.2.6.6. Financials (Based on Availability)